Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 1/20 | 0.60 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 5/20 | 0.52 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SCN4A | P35499 | 2/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118452 | 1.00 | UBE2M (0.60) | UBE2MDCUN1D1SIGMAR1FUCA1DRD4 | |
| SCHEMBL3121007 | 1.00 | UBE2M (0.60) | UBE2MDCUN1D1SIGMAR1FUCA1DRD4 | |
| SCHEMBL2221237 | 1.00 | UBE2M (0.60) | UBE2MDCUN1D1SIGMAR1FUCA1DRD4 | |
| SCHEMBL3121018 | 1.00 | UBE2M (0.60) | UBE2MDCUN1D1SIGMAR1FUCA1DRD4 | |
| SCHEMBL9721654 | 0.88 | DRD4 (0.61) | UBE2MDCUN1D1SIGMAR1DRD4DRD2 | |
| SCHEMBL9721671 | 0.88 | DRD4 (0.61) | UBE2MDCUN1D1SIGMAR1DRD4DRD2 | |
| SCHEMBL9721659 | 0.88 | DRD4 (0.61) | UBE2MDCUN1D1SIGMAR1DRD4DRD2 | |
| SCHEMBL4290080 | 0.87 | FUCA1 (0.61) | UBE2MDCUN1D1SIGMAR1FUCA1DRD4 | |
| SCHEMBL4290083 | 0.87 | FUCA1 (0.61) | UBE2MDCUN1D1SIGMAR1FUCA1DRD4 | |
| SCHEMBL2181704 | 0.87 | UBE2M (0.56) | UBE2MDCUN1D1SIGMAR1FUCA1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351738-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL | Sumitomo Chemical Company, Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | TEAD4, TEAD3, TEAD2 | UBE2M 4657/4885DCUN1D1 3426/4885SIGMAR1 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.